Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals moves boss to US

GW Pharmaceuticals moves boss to US
Cannabis growing shed

GW Pharmaceuticals (LON:GWP) is shifting its chief executive to the US to spearhead the company’s overseas development of its cannabis-based drugs.

Justin Gover is moving to GW’s new base in Southern California, where he will oversee the creation of a US business.

It has also appointed the former president of US drug group Allergan’s North American pharmaceutical  division, Julian Gangolli, as the president of its own operation in the region.

GW  commercialised the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for treating spasticity due to multiple sclerosis in 27 countries outside the US.

It is also developing a childhood epilepsy drug called Epidiolex as well as treatments for pain associated with advanced cancer, glioma, type 2 diabetes and schizophrenia.

It will be hoping to benefit from the increasing liberalisation of cannabis laws in the US, where some states have authorised its use as a medication.

As president of the North American pharmaceutical division of Allergan from 2004 to April this year, Gangolli ran a 1,400-strong commercial operation with sales topping $3.8bn last year.

GW’s chairman Geoffrey Guy said: "As Epidiolex nears its final stages of clinical development and as GW prepares for future US launch, the time is right to start building our in-house US commercial infrastructure.

“Julian's experience at building and running a major US pharmaceutical business built on specialty products will be complemented by the re-location of Justin to the US with his intimate knowledge of GW, its products and pipeline. Together, they will spearhead GW's US growth."

 

GW is also expanding manufacturing and research & development operations in the UK, where it employs 325 staff, up from 190 two years ago. Shares in GW rose 7.5p or 1.3% to 603.5p at 14:47 in London.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
Cannabis leaf
10:00
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use